Compare FTAI Aviation Ltd (FTAI) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Illumina, Inc. — how do they compare? FTAI Aviation Ltd trades at $207.28 (market cap $21.93B), while Illumina, Inc. trades at $189.22 (market cap $28.32B). The key difference: Illumina, Inc. is the larger of the two by market cap, and FTAI Aviation Ltd pays a 0.7% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| FTAI | ILMN | |
|---|---|---|
Market Cap | $21.93B | $28.32B |
Sector | Industrials | Health |
52-Week High | $310.04 | $194.33 |
52-Week Low | $109.92 | $91.00 |
Enterprise Value | $24.97B | $29.70B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $205.71, down 0.25% with a bearish technical outlook despite unanimous analyst buy ratings. The company reported strong revenue growth to $2.51 billion in 2025 with 19% net margins, though recent quarters show earnings misses. Positive developments include a strategic Boeing 737-800 freighter collaboration and expansion into data center power solutions, while negative operating cash flow raises execution concerns.
The stock presents growth potential from aerospace servicing and new power segment opportunities, but faces risks from consistent earnings misses and high valuations (P/E 42.6). Institutional sentiment remains strongly positive with 100% buy ratings, though technical indicators suggest near-term pressure with support at $195.
Illumina (ILMN) trades at $191.20, up 0.61% with strong technical momentum near 52-week highs. The company shows robust fundamentals with consistent earnings beats, 19.42% net margin, and improving cash flow. Recent leadership appointments and product launches support growth narrative. Technical indicators show bullish momentum with support at $188 and resistance at $194.
Outlook remains positive with strong sequencing demand and margin expansion driving recovery. Risks include competition from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings but price target of $174.44 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
